Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Development Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,592 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 400 · Balance 52,592 F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:08 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 400 | $2.01 | $804.00 |
DisclosureSEC source: 0000905148-26-003838 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,592 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:29 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 38,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002551 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,992 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 404 | $1.92 | $775.68 |
DisclosureSEC source: 0000905148-26-002500 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,408 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:17 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 94,946 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001117 · form4.xml · derivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,946 Underlying: Common Stock · 94,946 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 471 | $1.63 | $767.73 |
DisclosureSEC source: 0000905148-26-000936 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,812 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 403 | $2.24 | $902.72 |
DisclosureSEC source: 0000905148-25-004129 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,283 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:16 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 403 | $1.39 | $560.17 |
DisclosureSEC source: 0000905148-25-003041 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,686 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:18 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 403 | $1.14 | $459.42 |
DisclosureSEC source: 0000905148-25-001822 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,089 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:24 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 78,078 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000836 · form4.xml · derivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,078 Underlying: Common Stock · 78,078 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:54 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 469 | $5.42 | $2,541.98 |
DisclosureSEC source: 0000905148-25-000727 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,492 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:29 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 402 | $7.92 | $3,183.84 |
DisclosureSEC source: 0000905148-24-003225 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,961 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:50 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 402 | $7.02 | $2,822.04 |
DisclosureSEC source: 0000905148-24-002279 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,363 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2024 Filed May 16, 2024 22:58 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 402 | $8.36 | $3,360.72 |
DisclosureSEC source: 0000905148-24-001487 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,765 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Nov 27, 2024 23:08 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 45,045 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003291 · form4.xml · derivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2034-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 468 | $3.40 | $1,591.20 |
DisclosureSEC source: 0000905148-24-000762 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,167 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:41 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 1,395 | $5.08 | $7,086.60 |
DisclosureSEC source: 0000905148-23-001474 · form4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,635 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 60,090 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-22-057400 · doc4.xml · derivative · entry 2 Gamelin Erick · CIK 0001950551 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,090 Underlying: Common Stock · 60,090 shares Expires 2032-11-13 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057400 · doc4.xml · nonDerivative · entry 1 Gamelin Erick · CIK 0001950551 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,030 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.